01

Tulisokibart Hits Primary Endpoint in Phase 2b HS Trial

Tulisokibart met its primary endpoint in a Phase 2b hidradenitis suppurativa trial, advancing a new anti-TNF candidate toward Phase 3 in a field with few approved biologics.